

TRANSMITTAL LETTER TO THE UNITED STATES  
DESIGNATED/ELECTED OFFICE (DO/EO/US)  
CONCERNING A FILING UNDER 35 U.S.C. §371

U.S. APPLICATION NO.  
(if known, enter 371(c)(1) or (2))  
NEW **10/009835**

International Application No.  
PCT/JP00/03923

International Filing Date  
June 16, 2000

Priority Date Claimed  
June 18, 1999

Title of Invention  
QUICKLY DISINTEGRATING SOLID PREPARATIONS

Applicant(s) For DO/EO/US  
Kazuhiro OHKOUCHI and Hiroyoshi KOYAMA


Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. §371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. §371.
3. ☐ This express request to begin national examination procedures (35 U.S.C. §371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. §371(b) and PCT Articles 22 and 39(1).
4. ☒ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. ☒ A copy of the International Application as filed (35 U.S.C. §371(c)(2))
  - a. ☐ is transmitted herewith (required only if not transmitted by the International Bureau).
  - b. ☒ has been transmitted by the International Bureau.
  - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US)
6. ☒ A translation of the International Application into English (35 U.S.C. §371(c)(2)). **ATTACHMENT A**
  - a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
  - b. ☐ have been transmitted by the International Bureau.
  - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
  - d. ☐ have not been made and will not be made.
7. ☐ A translation of the amendments to the claims under PCT Article 19.
8. ☒ An executed oath or declaration of the inventor(s) (35 U.S.C. §371(c)(4)). **ATTACHMENT B**
9. ☐ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. §371(c)(5)).

Items 11. to 14. below concern other document(s) or information included:

11. ☒ An Information Disclosure Statement under 37 CFR 1.97 and 1.98. **ATTACHMENT C**
12. ☒ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.  
**ATTACHMENT D**
13. ☐ A **FIRST** preliminary amendment.  
☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
14. ☐ Other items or information:

THE COMMISSIONER IS AUTHORIZED  
TO CHARGE ANY DEFICIENCY IN THE  
FEE FOR THIS PAPER TO DEPOSIT  
ACCOUNT NO. 23-0975.

U.S. APPLICATION NO. <b>10/009835</b> NEW		INTERNATIONAL APPLICATION NO. PCT/JP00/03923		ATTORNEY'S DOCKET NO. 2001 1692A	
15. <input checked="" type="checkbox"/> The following fees are submitted				CALCULATIONS	PTO USE ONLY
<b>BASIC NATIONAL FEE (37 CFR 1.492(a)(1)-(5)):</b> Neither international preliminary examination fee nor international search fee paid to USPTO and International Search Report not prepared by the EPO or JPO ..... \$1040.00 International Search Report has been prepared by the EPO or JPO ..... \$ 890.00 International preliminary examination fee not paid to USPTO but international search paid to USPTO ..... \$ 740.00 International preliminary examination fee paid to USPTO but claims did not satisfy provisions of PCT Article 33(1)-(4) ..... \$ 690.00 International preliminary examination fee paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4) ..... \$ 100.00					
<b>ENTER APPROPRIATE BASIC FEE AMOUNT =</b>				\$890.00	
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).				\$	
Claims	Number Filed	Number Extra	Rate		
Total Claims	32 -20 =	12	X \$18.00	\$216.00	
Independent Claims	- 3 =		X \$84.00	\$	
Multiple dependent claim(s) (if applicable)				+ \$280.00	\$
<b>TOTAL OF ABOVE CALCULATIONS =</b>				\$1,106.00	
<input type="checkbox"/> Small Entity Status is hereby asserted. Above fees are reduced by 1/2.				\$	
<b>SUBTOTAL =</b>				\$1,106.00	
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).				+	\$
<b>TOTAL NATIONAL FEE =</b>				\$1,106.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40 per property +				\$40.00	
<b>TOTAL FEES ENCLOSED =</b>				\$1,146.00	
				Amount to be refunded	\$
				Amount to be charged	\$
a. <input checked="" type="checkbox"/> A check in the amount of <b>\$1,146.00</b> to cover the above fees is enclosed. A duplicate copy of this form is enclosed. b. <input type="checkbox"/> Please charge my Deposit Account No. 23-0975 in the amount of \$_____ to cover the above fees. A duplicate copy of this sheet is enclosed. c. <input type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>23-0975</u> .					
<b>NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or          (b)) must be filed and granted to restore the application to pending status.</b>					
19. CORRESPONDENCE ADDRESS  <div style="text-align: center;">   <b>000513</b>          PATENT TRADEMARK OFFICE       </div>			By: <u>Warren M. Cheek, Jr.</u> Warren M. Cheek, Jr. Registration No. 33,367  WENDEROTH, LIND & PONACK, L.L.P. 2033 "K" Street, N.W., Suite 800 Washington, D.C. 20006-1021 Phone: (202) 721-8200 Fax: (202) 721-8250  December 17, 2001		

[CHECK NO. 47985]

[2001\_1692A]

QUICKLY DISINTEGRATING SOLID PREPARATIONS

## TECHNICAL FIELD

The present invention relates to solid preparations that disintegrate quickly in the presence of saliva or a small amount of water in the oral cavity, particularly those useful as intraorally disintegrating solid preparations.

## BACKGROUND ART

For aged people and children who are difficult to swallow drugs, solid preparations that disintegrate or dissolve quickly in the oral cavity have long been developed. For example, an intraorally disintegrating tablet preparation is described in the International Publication No. WO93/12769, which is obtained by suspending a drug, lactose, and mannitol in aqueous agar solution, filling the resulting suspension in a molding pocket or the like, and drying the molding under reduced pressure. This molding shows quick disintegration but is more fragile than usual tablets so that it is readily cracked, chipped, etc. and a long time is required for its production; thus the process for production is poor in productivity. In Japanese Patent Laying-Open No.6-218028(1994) and Japanese Patent Laying-Open No.8-

19589(1996), a process for production of a tablet preparation is described, where moist powder after kneading is filled in the tablet molding well for wet shaping followed by drying. The resulting tablet preparation, being porous and having a moderate void fraction, shows quick disintegration. However the industrial productivity of this process for production is poor because a wet material with low fluidity is filled and compressed so that the amount filled in each well varies greatly and a special dryer is necessary.

Then a few processes for production of an intraorally disintegrating tablet preparation by dry tableting excellent in productivity have also been reported. For example, a process for production of an intraorally disintegrating tablet preparation by dry tableting using a saccharide with a good moldability and a saccharide with a poor moldability in combination is described in the International Publication No. WO95/20380. Also a process for production of an intraorally disintegrating tablet preparation by dry tableting using granules obtained by wet or dry granulation using an excipient and erythritol, a sugar alcohol, in combination is described in the International Publication No. WO98/02185.

In addition, a process for production of a tablet

preparation that disintegrates quickly in the oral cavity, by combining a saccharide or a sugar alcohol having a mean particle diameter of not more than 30  $\mu\text{m}$ , an active ingredient, and a disintegrating agent is described in the International Publication No. WO97/47287. According to this process, the molding obtained by pulverization of a saccharide or a sugar alcohol, such as D-mannitol or lactose, followed by addition of a disintegrating agent, etc. and compression molding shows quick disintegration, whereas when coarse particles of a saccharide (lactose, mean particle diameter of 80  $\mu\text{m}$ ) or a sugar alcohol (D-mannitol, mean particle diameter of 60  $\mu\text{m}$ ) before pulverization are used, molding is difficult under a low tableting pressure and even the molding obtained under a high tableting pressure does not show a sufficient mechanical hardness.

D-mannitol is known to produce a very high friction (binding) at the surface of the mortar wall during compression molding. In addition, pulverization is undesirable not only because it strengthens the friction at the surface of the mortar wall but also from the viewpoint of handling because it reduces fluidity during the production of the tablet preparation (Summary of lectures at the 14<sup>th</sup> Symposium on Particulate Preparations and Designs, p.115 (1997), Handbook of Pharmaceutical

Excipients 2<sup>nd</sup> Ed., p.294 (1994), The Pharmaceutical Press).

#### DISCLOSURE OF THE INVENTION

5           The inventors have conducted extensive studies on intraorally disintegrating tablet preparations that can be industrially produced with common installations without requiring any special manufacturing technique. As the result of the studies, the inventors found that an  
10       intraorally disintegrating tablet preparation that has a practically not problematic hardness, disintegrates quickly, and has no problem in productivity can be obtained by dry tableting even under a low compression pressure when an active ingredient is combined with a  
15       relatively coarse powder of a saccharide or a sugar alcohol, a disintegrating agent, and a cellulose compound. As a result of further studies, the inventors have completed the present invention. That is, the invention relates to:

20       (1) a quickly disintegrating solid preparation comprising a) an active ingredient, b) a saccharide or a sugar alcohol with the mean particle diameter of 30  $\mu\text{m}$  to 300  $\mu\text{m}$  (not less than 30  $\mu\text{m}$  and not more 300  $\mu\text{m}$ ), c) a disintegrating agent, and d) a cellulose compound;

25       (2) the preparation according to the above-mentioned (1),

wherein the preparation is an intraorally quickly disintegrating solid preparation;

(3) the preparation according to the above-mentioned (1), wherein the preparation is a tablet preparation;

5 (4) the preparation according to the above-mentioned (1), wherein 40 to 95 parts of a saccharide or a sugar alcohol is contained in 100 parts of the solid preparation by weight;

10 (5) the preparation according to the above-mentioned (1), wherein 0.5 to 15 parts of a disintegrating agent is contained in 100 parts of the solid preparation by weight;

15 (6) the preparation according to the above-mentioned (1), wherein 0.5 to 40 parts of a cellulose compound is contained in 100 parts of the solid preparation by weight;

20 (7) the preparation according to the above-mentioned (1), wherein the saccharide is one or more saccharides selected from the group consisting of glucose, fructose, lactose, sucrose, and trehalose;

(8) the preparation according to the above-mentioned (1), wherein the saccharide is lactose;

25 (9) the preparation according to the above-mentioned (1), wherein the sugar alcohol is one or more sugar alcohols selected from the group consisting of D-mannitol,

erythritol, xylitol, maltitol, and sorbitol;

(10) the preparation according to the above-mentioned (1),  
wherein the sugar alcohol is D-mannitol;

(11) the preparation according to the above-mentioned (1),  
5 characterized in that D-mannitol with the mean particle  
diameter of 30  $\mu\text{m}$  to 300  $\mu\text{m}$  is used as the saccharide or  
sugar alcohol with the mean particle diameter of 30  $\mu\text{m}$  to  
300  $\mu\text{m}$ ;

(12) the preparation according to the above-mentioned (1),  
10 wherein the disintegrating agent is one or more  
disintegrating agents selected from the group consisting  
of carmellose calcium, carboxymethylstarch sodium,  
croscarmellose sodium, and crospovidone;

(13) the preparation according to the above-mentioned (1),  
15 wherein the cellulose compound is one or more substances  
selected from the group consisting of crystalline  
cellulose, powder cellulose, low substituted  
hydroxypropylcellulose, and carmellose;

(14) the preparation according to the above-mentioned (1),  
20 wherein the active ingredient is manidipine  
hydrochloride;

(15) the preparation according to the above-mentioned (1),  
wherein the active ingredient is voglibose;

(16) the preparation according to the above-mentioned (1),  
25 wherein the active ingredient is candesartan cilexetil;



(17) the preparation according to the above-mentioned (1), wherein the active ingredient is pioglitazone hydrochloride;

(18) the process for production of the preparation

5 according to the above-mentioned (1), characterized in that a mixture containing a) an active ingredient, b) a saccharide or sugar alcohol with the mean particle diameter of 30  $\mu\text{m}$  to 300  $\mu\text{m}$  (not less than 30  $\mu\text{m}$  and not more than 300  $\mu\text{m}$ ), c) a disintegrating agent, and d) a  
10 cellulose compound is molded by compression;

(19) a quickly disintegrating solid preparation

containing a) an active ingredient, b-1) a saccharide or sugar alcohol with the mean particle diameter of 5  $\mu\text{m}$  to below 90  $\mu\text{m}$  (not less than 5  $\mu\text{m}$  and below 90  $\mu\text{m}$ ), b-2) a  
15 saccharide or a sugar alcohol with the mean particle diameter of 90  $\mu\text{m}$  to 500  $\mu\text{m}$  (not less than 90  $\mu\text{m}$  and not more than 500  $\mu\text{m}$ ), c) a disintegrating agent, and d) a cellulose compound;

(20) the preparation according to the above-mentioned (19),  
20 containing 0.1 to 10 parts of the ingredient b-2) per 1 part of the ingredient b-1) by weight;

(21) the preparation according to the above-mentioned (19), characterized in that a mixture of the ingredient b-1) and the ingredient b-2) as the ingredient b-1) and the  
25 ingredient b-2);

(22) the preparation according to the above-mentioned (21), wherein the mean particle diameter of the mixture is 30  $\mu\text{m}$  to 300  $\mu\text{m}$  (not less than 30  $\mu\text{m}$  and not more than 300  $\mu\text{m}$ );

5 (23) the preparation according to the above-mentioned (19), wherein the mean particle diameter of the ingredient b-1) is 30  $\mu\text{m}$  to below 90  $\mu\text{m}$  (not less than 30  $\mu\text{m}$  and below 90  $\mu\text{m}$ );

10 (24) the preparation according to the above-mentioned (19), wherein the mean particle diameter of the ingredient b-1) is 35  $\mu\text{m}$  to 80  $\mu\text{m}$  (not less than 35  $\mu\text{m}$  and not more than 80  $\mu\text{m}$ );

(25) the preparation according to (19), wherein the mean particle diameter of the ingredient b-2) is 90  $\mu\text{m}$  to 300  $\mu\text{m}$  (not less than 90  $\mu\text{m}$  and not more than 300  $\mu\text{m}$ );

15 (26) the preparation according to the above-mentioned (19), wherein the mean particle diameter of the ingredient b-2) is 90  $\mu\text{m}$  to 200  $\mu\text{m}$  (not less than 90  $\mu\text{m}$  and not more than 200  $\mu\text{m}$ );

20 (27) the preparation according to the above-mentioned (19), wherein the saccharide is one or more saccharides selected from the group consisting of glucose, fructose, lactose, sucrose, and trehalose;

25 (28) the preparation according to the above-mentioned (19), wherein the saccharide is lactose;

(29) the preparation according to the above-mentioned (19), wherein the sugar alcohol is one or more sugar alcohols selected from the group consisting of D-mannitol, erythritol, xylitol, maltitol, and sorbitol;

(30) the preparation according to the above-mentioned (19), wherein the sugar alcohol is D-mannitol;

(31) the preparation according to the above-mentioned (19), characterized in that D-mannitol with the mean particle diameter of 30  $\mu\text{m}$  to 90  $\mu\text{m}$  and D-mannitol with the mean particle diameter of 90  $\mu\text{m}$  to 300  $\mu\text{m}$  are used as the ingredient b-1) and the ingredient b-2), respectively;

(32) the process for production of a preparation according to the above-mentioned (19), characterized in that a mixture containing a) an active ingredient, b-1) a saccharide or a sugar alcohol with the mean particle diameter of 5  $\mu\text{m}$  to below 90  $\mu\text{m}$  (not less than 5  $\mu\text{m}$  and below 90  $\mu\text{m}$ ), b-2) a saccharide or a sugar alcohol with the mean particle diameter of 90  $\mu\text{m}$  to 500  $\mu\text{m}$  (not less than 90  $\mu\text{m}$  and not more than 500  $\mu\text{m}$ ), c) a disintegrating agent, and d) a cellulose compound is molded by compression; etc.

Active ingredients used in the present invention may be in any form, i.e. solid, crystal, oil, or solution, and one or more agents selected from the group consisting of, for example, alimentary roborants, antipyretic

analgesic antiphlogistics, psychotropic agents,  
 anxiolytics, anti-depressants, hypnotic sedatives,  
 antispasmodics, central nervous system acting drugs,  
 cerebral metabolism improving agents, cerebral  
 5 circulation improving agents, antiepileptics,  
 sympathomimetics, digestives, antacids, antiulcer agents,  
 antitussive expectorants, antiemetics, respiratory  
 stimulants, bronchodilators, antiallergic agents, dental  
 stomatic agents, anti-histamines, cardiacs,  
 10 antiarrhythmic agents, diuretics, hypotensive agents,  
 angiotonics, coronary vasodilators, peripheral  
 vasodilators, antihyperlipemic drugs, cholagogues,  
 antibiotics, chemotherapeutics, antidiabetic agents,  
 osteoporosis treating drugs, antirheumatics, skeletal  
 15 muscle relaxants, antispasmodic drugs, hormone drugs,  
 alkaloid narcotics, sulfa drugs, gout treating agents,  
 anticoagulants, antineoplastic agents, and the like are  
 used.

Alimentary roborants include vitamins such as  
 20 vitamin A, vitamin D, vitamin E (d- $\alpha$ -tocopherol acetate,  
 etc.), vitamin B1 (dibenzoyl thiamine, fursultiamine  
 hydrochloride, etc.), vitamin B2 (riboflavin butyrate,  
 etc.), vitamin B6 (pyridoxine hydrochloride, etc.),  
 vitamin C (ascorbic acid, sodium L-ascorbate, etc.), and  
 25 vitamin B12 (hydroxocobalamin acetate, cyanocobalamin,

etc.), minerals such as calcium, magnesium, iron, etc., protein, amino acids, oligosaccharides, crude drugs, and the like.

Antipyretic analgesic antiphlogistics include

- 5 aspirin, acetaminophen, ethenzamide, ibuprofen, diphenhydramine hydrochloride, chlorpheniramine di-  
maleate, dihydrocodeine phosphate, noscapine, methylephedrine hydrochloride, phenylpropanolamine  
hydrochloride, caffeine, anhydrous caffeine, serrapeptase,  
10 lysozyme chloride, tolfenamic acid, mefenamic acid, diclofenac sodium, flufenamic acid, salicylamide, aminopyrine, ketoprofen, indometacin, bucolome, pentazocine, and the like.

Psychotropic agents include chlorpromazine,

- 15 reserpine, and the like. Anxiolytics include alprazolam, chlordiazepoxide, diazepam, and the like.

Antidepressants include imipramine, maprotiline hydrochloride, amphetamine, and the like. Hypnotic sedatives include estazolam, nitrazepam, diazepam,

- 20 perlapine, phenobarbital sodium, and the like.

Antispasmodics include scopolamine hydrobromide, diphenhydramine hydrochloride, papaverine hydrochloride, and the like. Central nervous system acting agents include citicoline, and the like. Cerebral metabolism

- 25 improving agents include meclofenoxate hydrochloride, and



Dental stomatic agents include oxytetracycline, triamcinolone acetonide, chlorhexidine hydrochloride, lidocaine, and the like.

Antihistamines include diphenhydramine hydrochloride, promethazine, isothipendyl hydrochloride, chlorpheniramine dl-maleate, and the like.

Cardiacs include caffeine, digoxin, and the like.

Antiarrhythmic agents include procainamide hydrochloride, propranolol hydrochloride, pindolol, and the like.

Diuretics include isosorbide, furosemide, hydrochlorothiazide, and the like. Hypotensive agents include derapril hydrochloride, captopril, hydralazine hydrochloride, labetalol hydrochloride, manidipine hydrochloride, candesartan cilexetil, methyldopa, perindopril erbumine, and the like. Angiotonics include phenylephrine hydrochloride, and the like. Coronary vasodilators include carbocromen hydrochloride, molsidomine, verapamil hydrochloride, and the like. Peripheral vasodilators include cinnarizine, and the like.

Antihyperlipemic agents include cerivastatin sodium, simvastatin, pravastatin sodium, atorvastatin calcium hydrate, and the like.

Cholagogues include dehydrocholic acid, trepibutone, and the like.

Antibiotics include cefems such as cefalexin,

cefaclor, amoxicillin, pivmecillinam hydrochloride, cefotiam hexetil hydrochloride, cefadroxil, cefixime, cefditoren pivoxil, ceftaram pivoxil, cefpodoxime proxetil, etc., synthetic ones such as ampicillin, 5 ciclacillin, nalidixic acid, enoxacin, etc., monobactams such as carumonam sodium, penems, carbapenems, and the like.

Chemotherapeutics include sulfamethizole, and the like.

10 Antidiabetic agents include tolbutamide, voglibose, pioglitazone hydrochloride, glibenclamide, troglitazone, and the like.

Osteoporosis treating drugs include ipriflavone, and the like.

15 Skeletal muscle relaxants include methocarbamol, and the like.

Antispasmodic drugs meclizine hydrochloride, dimenhydrinate, and the like.

20 Antirheumatics include methotrexate, bucillamine, and the like.

Hormone drugs include liothyronine sodium, dexamethasone phosphate, predonisolone, oxendolone, leuporelin acetate, and the like.

25 Alkaloid narcotics include opium, morphine hydrochloride, ipecac, oxycodone hydrochloride, opium



alkaloids hydrochloride, cocaine hydrochloride, and the like.

Sulfa drugs include sulfisomidine, sulfamethizole, and the like.

5 Gout treating drugs include allopurinol, colchicine, and the like.

Anticoagulants include dicoumarol, and the like.

Antineoplastic drugs include 5-fluorouracil, uracil, mitomycin, and the like.

10 Among these, manidipine hydrochloride, voglibose, candesartan cilexetil, pioglitazone hydrochloride, etc., particularly manidipine hydrochloride, are used preferably.

15 The active ingredient may be the one diluted with a diluent used generally in the fields of medicine and foods. An active ingredient after treatment for masking the bitterness of the active ingredient may also be used.

The amount of the active ingredient varies depending on the nature and dose of the active ingredient, and is 20 0.01 to 40 parts, preferably 0.01 to 20 parts, per 100 parts by weight of the solid pharmaceutical preparation of the invention.

Saccharides used in the invention include glucose, fructose, lactose, sucrose, trehalose, and the like, 25 among which lactose is used preferably.

Sugar alcohols used in the invention include D-mannitol, erythritol, xylitol, maltitol, sorbitol, and the like, among which D-mannitol is used preferably.

One or more saccharides or one or more sugar alcohols may be used in combination, or a combination of a saccharide and a sugar alcohol may be used.

The mean particle diameter of the saccharide or the sugar alcohol (preferably the sugar alcohol, or more preferably D-mannitol) is 30 to 300  $\mu\text{m}$  (measured by, for example, the laser diffraction particle size analyzer, SYMPATEC Co.: HELOS & RODOS, etc.), preferably above 30  $\mu\text{m}$ , more preferably 31  $\mu\text{m}$  or more, and further more preferably 35 to 200  $\mu\text{m}$ . Saccharides or sugar alcohols of such a particle size are commercially available (Lactose 100M and Lactose 200M of DMV, granulated powder lactose Dilactose R and Dilactose S of Freund Industry Co., Ltd., Tablettose and Flowlac 100 of Meggle Japan, Mannit S and Marinecrystal of Towa Chemical Industry Co., Ltd., 1.05980 of Merck Co., Mannidex of Cerestar Japan, Ltd., Trehalose P of Asahi Chemical Industry Co., Ltd., Sorbitol DP-50M and Amalty MR-50 of Towa Chemical Industry Co., Ltd., Pure Fructose S of Kato Kagaku, and the like). Saccharides and sugar alcohols with the mean particle diameter of 5 to 30  $\mu\text{m}$  are commercially available (Granulac 230 and Solvolac 400 of Meggle Japan,

Mannit P, Xylit P, and Amalty MR-100 of Towa Chemical Industry Co., Ltd., Erythritol (fine powder) of Nikken Chemicals Co., Ltd., and the like). Saccharides and sugar alcohols with the mean particle diameter of 200 to 500  $\mu\text{m}$  are commercially available (Sachelac 80 of Meggle Japan, Trehalose G and Xylitol XC of Asahi Chemical Industry Co., Ltd., Erythritol of Nikken Chemicals Co., Ltd., Anhydrous crystalline glucose TDA-S and Hydrated crystalline glucose TDH of San-ei Sucrochemical Co., Ltd., and the like). In addition, saccharides and sugar alcohols with the mean particle diameter of not less than 500  $\mu\text{m}$  are commercially available (Prismalac 40 of Meggle Japan, Pure Fructose of Kato Kagaku, Amalty MR-20 and Sorbitol DP-10M of Towa Chemical Industry Co., Ltd., and the like). A saccharide or sugar alcohol with the necessary mean particle diameter may be obtained by a method such as pulverization from the commercially available product. Pulverization is performed by using a cutter mill, jet mill, hammer mill, or the like.

A saccharide or sugar alcohol with the mean particle diameter of 5  $\mu\text{m}$  to below 90  $\mu\text{m}$  (preferably 30 to below 90  $\mu\text{m}$ ) to strengthen the molding may be combined with a saccharide or sugar alcohol with the mean particle diameter of 90  $\mu\text{m}$  to 500  $\mu\text{m}$  (preferably 90  $\mu\text{m}$  to 300  $\mu\text{m}$ ) to increase fluidity during manufacturing. In

combination of a fine powder of a saccharide or sugar alcohol with the mean particle diameter of 5  $\mu\text{m}$  to below 90  $\mu\text{m}$  (preferably 30 to below 90  $\mu\text{m}$ , more preferably 35 to 80  $\mu\text{m}$ ) with a coarse powder of a saccharide or sugar alcohol with the mean particle diameter of 90  $\mu\text{m}$  to 500  $\mu\text{m}$  (preferably 90  $\mu\text{m}$  to 300  $\mu\text{m}$ , more preferably 90 to 200  $\mu\text{m}$ ), it is recommendable to use one part of a fine powder of a saccharide or sugar alcohol with 0.1 to 10 parts, preferably 0.2 to 5 parts, of a coarse powder of a saccharide or sugar alcohol by weight. Particularly when the active ingredient is manidipine hydrochloride, it is recommendable to use one part of a fine powder of a saccharide or sugar alcohol usually with 0.2 to 3.5 parts, preferably with 0.3 to 2.5 parts, of a coarse powder of a saccharide or sugar alcohol by weight.

In combination of a fine powder of a saccharide or sugar alcohol with a coarse powder of a saccharide or sugar alcohol, one or more saccharides or one or more sugar alcohols may be combined, or a fine powder of a saccharide or sugar alcohol may be combined with a coarse powder of the same or a different saccharide or sugar alcohol. In addition, a mixture obtained by mixing a fine powder of a saccharide or sugar alcohol with a coarse powder of a saccharide or sugar alcohol may be molded into a quickly disintegrating solid preparation of

the invention, or a fine powder of a saccharide or sugar alcohol and a coarse powder of a saccharide or sugar alcohol are divided into two or more groups to prepare granules, followed by molding into the quickly  
5 disintegrating solid preparation of the invention.

When the mixture of a fine powder of a saccharide or sugar alcohol with a coarse powder of a saccharide or sugar alcohol is used as the starting material, the mixture has desirably two or more peaks in the particle  
10 size distribution and the mean particle diameter of the mixture is desirably 30  $\mu\text{m}$  to 300  $\mu\text{m}$ .

A desirable combination of a fine powder of a saccharide or sugar alcohol with a coarse powder of a saccharide or sugar alcohol is exemplified by the mixture  
15 of D-mannitol with the mean particle diameter of 30  $\mu\text{m}$  to below 90  $\mu\text{m}$  with D-mannitol with the mean particle diameter of 90  $\mu\text{m}$  to 300  $\mu\text{m}$ .

The amount of a saccharide or sugar alcohol used is 40 to 95 parts, preferably 50 to 90 parts, per 100 parts  
20 of the solid pharmaceutical preparation by weight.

Disintegrating agents used include carmellose calcium, carboxymethyl starch sodium, croscarmellose sodium, crospovidone, and the like, and 0.5 to 15 parts, preferably 1 to 10 parts, thereof is used per 100 parts  
25 of the solid pharmaceutical preparation by weight.

Disintegrating agents are exemplified by  
Crospovidone [manufactured by ISP Inc. (USA), BASF  
(Germany)], Croscarmellose Sodium (FMC- Asahi Chemical  
Industry Co., Ltd.), Carmellose Calcium (Gotoku Yakuhin  
5 Co., Ltd.), and Carboxymethylstarch Sodium (Matsutani  
Kagaku Co., Ltd., Kimura Sangyo Co., Ltd., etc.).

The crospovidone product may be any cross-linked  
polymer that is 1-ethenyl-2-pyrrolidinone homopolymer,  
and usually a crospovidone product having a molecular  
10 weight of 1,000,000 or more is used. Examples of  
commercially available crospovidone products are Cross-  
linked Povidone, Kollidon CL [manufactured by BASF  
(Germany)], Polyplasdone XL, X1-10, and INF-10  
[manufactured by ISP Inc. (USA)].

15 Cellulose compounds used are crystalline cellulose,  
powder cellulose, low substituted hydroxypropylcellulose,  
carmellose, and the like, and 0.5 to 40 parts, preferably  
1 to 20 parts, thereof is used for 100 parts of the solid  
pharmaceutical preparation by weight.

20 Examples of crystalline cellulose products are  
CEOLUS KG801, Avicel PH101, PH102, PH301, PH302, and PH-  
F20, Avicel RC-A591NF (all manufactured by Asahi Chemical  
Industry Co., Ltd.), and the like, including also fine  
crystalline cellulose.

25 Examples of low substituted hydroxypropylcellulose

products are low substituted hydroxylpropylcellulose of which content of hydroxypropoxyl group is 5 to 16% by weight such as Low Substituted Hydroxypropylcellulose LH11, LH21, LH31, LH22, LH32, LH20, LH30, LH32, and LH33 (all manufactured by Shin-Etsu Chemical Co., Ltd.), and the like. These are commercially available. Low substituted hydroxypropylcellulose can be produced by a publicly known procedure, for example the procedure described in Patent Gazette No.57-53100(1982), or a similar procedure.

Active ingredients, disintegrating agents, and cellulose compounds may be used in combination of one or more of each.

The preparation of the invention may contain a starch product as an excipient such as corn starch, potato starch, wheat starch, rice starch, partially gelatinized starch, gelatinized starch, porous starch, and the like, and various additives used for production of general pharmaceutical preparations, in their respective suitable amounts, unless they interfere with the effect of the invention. Such additives include excipients, binders, sour agents, foaming agents, artificial sweeteners, flavoring agents, lubricants, colorants, stabilizers, pH-modifiers, surfactants, and the like.

Excipients include inorganic excipients such as anhydrous calcium phosphate, precipitated calcium carbonate, calcium silicate, light anhydrous silicic acid, and the like.

5 Binders include hydroxypropylcellulose, hydroxypropylmethylcellulose, polyvinylpyrrolidone, powdered acacia, gelatin, pullulan, and the like.

Sour agents include citric acid, tartaric acid, malic acid, ascorbic acid, and the like.

10 Foaming agents include sodium bicarbonate, sodium carbonate, and the like. Sweeteners include saccharin sodium, dipotassium glycyrrhizinate, aspartame, stevia, thaumatin, and the like.

15 Flavoring agents include lemon oil, orange oil, menthol, and the like.

Lubricants include magnesium stearate, sucrose esters of fatty acid, polyethyleneglycol, talc, stearic acid, sodium stearyl fumarate, and the like.

20 Colorants include those for food such as Food Yellow No.5, Food Red No.2, Food Blue No.2, and the like, food lake colorants, ferric oxide, and the like.

Stabilizers include disodium edetate, tocopherol, cyclodextrin, and the like.

25 pH-Modifiers include citrates, phosphates, carbonates, tartarates, fumarates, acetates, amino acid

1000000-1000000



salts.

Surfactants include sodium lauryl sulfate, polysorbate 80, hydrogenated oil, polyoxyethylene(160)polyoxypropylene(30)glycol, and the like.

The particle diameter of these substances is not particularly limited, but the particle diameter is preferably not more than 500  $\mu\text{m}$  not to cause rough feeling in the mouth. These excipients may be used separately or in combination of two or more thereof.

A fine granular nucleus may be used for manufacturing of the solid preparation of the invention, and such a nucleus may be coated with active ingredients and additives etc. followed by further coating by a publicly known procedure for masking of the taste/odor, for enteric coating, for making the preparation into a sustained release form, and for other purposes.

The solid preparation of the invention can be produced either by compression molding of a mixture comprising a) an active ingredient, b) a saccharide or sugar alcohol with the mean particle diameter of 30  $\mu\text{m}$  to 300  $\mu\text{m}$ , c) a disintegrating agent, and d) a cellulose compound, or by compression molding of a mixture comprising a) an active ingredient, b-1) a saccharide or sugar alcohol with the mean particle diameter of 5  $\mu\text{m}$  to

below 90  $\mu\text{m}$ , b-2) a saccharide or sugar alcohol with the mean particle diameter of 90  $\mu\text{m}$  to 500  $\mu\text{m}$ , c) a disintegrating agent, and d) a cellulose compound.

The procedures for production by dividing the

starting materials into two groups are exemplified by:

[1] compression molding by mixing a group comprising a) an active ingredient, b-1) a saccharide or sugar alcohol with the mean particle diameter of 5  $\mu\text{m}$  to below 90  $\mu\text{m}$ , c) a disintegrating agent, and d) a cellulose compound, and a group comprising b-2) a saccharide or sugar alcohol with the mean particle diameter of 90  $\mu\text{m}$  to 500  $\mu\text{m}$ , c) a disintegrating agent, and d) a cellulose compound, followed by addition of a fluidizing agent, lubricant, sweetener, and/or the like in their respective suitable amounts, as needed;

[2] compression molding by mixing a group comprising a) an active ingredient, b-1) a saccharide or sugar alcohol with the mean particle diameter of 5  $\mu\text{m}$  to below 90  $\mu\text{m}$ , and c) a disintegrating agent, and a group comprising b-2) a saccharide or sugar alcohol with the mean particle diameter of 90  $\mu\text{m}$  to 500  $\mu\text{m}$ , c) a disintegrating agent, and d) a cellulose compound, followed by addition of a cellulose compound, fluidizing agent, lubricant, sweetener, and/or the like in their respective suitable amounts as needed;

[3] compression molding by mixing a group comprising a) an active ingredient, b-1) a saccharide or sugar alcohol with the mean particle diameter of 5  $\mu\text{m}$  to below 90  $\mu\text{m}$ , b-2) a saccharide or sugar alcohol with the mean particle diameter of 90  $\mu\text{m}$  to 500  $\mu\text{m}$ , c) a disintegrating agent, and d) a cellulose compound as needed, and a group comprising b-1) a saccharide or sugar alcohol with the mean particle diameter of 5  $\mu\text{m}$  to below 90  $\mu\text{m}$ , b-2) a saccharide or sugar alcohol with the mean particle diameter of 90  $\mu\text{m}$  to 500  $\mu\text{m}$ , c) a disintegrating agent, and d) a cellulose compound, followed by addition of a cellulose compound, fluidizing agent, lubricant, sweetener, and/or the like in their respective suitable amounts as needed.

The concrete procedures for production include the procedure that an active ingredient and the raw materials of the preparation are mixed in a mixer followed by immediate tableting. Also the procedure that the materials are dry compressed into tablets by the slugging method or roller-compacter method, the procedure for production of granules for tablets by dry tableting using water, acetone, ethyl alcohol, propyl alcohol, or a mixture thereof, in which a binder, if necessary, has been dispersed or dissolved, and the procedure for production of granules for tablets after dividing the

materials into two or more groups may be applicable. For production of tablets from granules for tablets, a cellulose compound, a disintegrating agent, a fluidizing agent, a lubricant, a flavoring agent, a sweetener, and the like may be mixed as needed.

Tablets are molded by using, for example, a single tableting machine, rotary tableting machine, and the like. Pressure for tableting is usually 2.5 to 30 kN/cm<sup>2</sup>. The shape of the solid preparation of the invention is not particularly restricted; the tablet may be round, caplet, doughnut, oblong, etc. or a multilayer tablet, a dry-coated tablet, or the like, and may be covered by coating. The tablet may have marks and letters for identification, and a nick on the surface.

The resultant quickly disintegrating solid preparation, preferably intraorally quickly disintegrating solid preparation, more preferably, intraorally quickly disintegrating tablet of the invention is quickly disintegrated in the oral cavity and has an adequate hardness. It is excellent also in productivity.

Namely, the time required for intraoral disintegration or dissolution (the time till the tablet is completely disintegrated by the action of the saliva in the oral cavity of healthy adult men and women) of the

intraorally quickly disintegrating tablet of the invention varies depending to the size and thickness of the tablet, being normally 5 to 90 seconds, preferably about 5 to 60 seconds. The hardness (measured by the tablet hardness meter) is normally 10 to 200N, preferably about 10 to 150 N.

Therefore the intraorally disintegrating tablet of the invention, like the conventional pharmaceutical preparations containing active ingredients, can be used for treatment and prevention of various diseases as a tablet easy to be taken by patients, aged people, and children who are difficult to swallow the medicine, and as a safe preparation in emergency for general adult people, and is excellent in long-term storage and stability.

The preparation may be orally taken without being disintegrated in the oral cavity, or taken with water. The preparation may also be orally taken after being dissolved in water in a cup or the like.

#### The Best Mode for Carrying Out the Invention

The invention is explained in more detail with the following Examples and Comparative Examples, though these Examples do not limit the invention.

### Examples

The tablet preparations obtained in the Examples and in the Comparative Examples were subjected to the test methods described below for measurement of the hardness and the intraoral disintegration time. Also productivity was assessed based on the observation of fluidity, binding property, and adhesion of powder to the surface of the punch during production of the tablet.

#### (1) Hardness test

Hardness was measured with the tablet hardness meter (Toyama Sangyo Co., Ltd.). Hardness of each of 5 or 10 tablets was measured, and expressed in the mean of the measurements.

#### (2) Intraoral disintegration time

The time till disintegration of the tablet in the presence of saliva alone in the oral cavity was measured in 3 healthy adult men (35, 49, and 51 years old).

### Example 1

A 40 g portion of manidipine hydrochloride, 303.4 g of D-mannitol (Towa Chemical Industry Co., Ltd.: Mannit S, mean particle diameter of 130  $\mu$ m), 50 g of crystalline cellulose (Asahi Chemical Industry Co., Ltd.), 50 g of corn starch (Japan Corn Starch), and 1 g of light anhydrous silicic acid (YKF) were placed in a fluidized

bed granulating dryer (Powrex Co., LAB-1 type), and 139 g of purified water containing 18 g of D-mannitol and 0.6 g of yellow ferric oxide (Anstead) was sprayed, followed by granulating and drying processes, to give granules.

5 To 347 g of the granules, 25 g of crospovidone (ISP Inc.), 1 g of light anhydrous silicic acid, 10 g of magnesium stearate (Taihei Kagaku Sangyo Co. Ltd.), and 1 g of aspartame (Ajinomoto Co. Ltd.) were added, to give a mixed powder.

10 This mixed powder was tabletted into tablets weighing 250 mg each (Kikusui Seisakusho, Correct 12HUK, tablet size of 9.5 mm $\phi$ , compression pressure of 9.8 kN (1 ton)/cm<sup>2</sup>).

15 Example 2

A 180 g portion of manidipine hydrochloride, 495 g of D-mannitol (Merck Co.: 1.05980, mean particle diameter of 45  $\mu$ m), 225 g of corn starch, 112.5 g of crystalline cellulose, 2 g of light anhydrous silicic acid, and 56.3 g of crospovidone were placed in a fluidized bed granulating dryer (Powrex Co., FD-3SN type), and 540 g of purified water containing 42.8 g of D-mannitol and 1.4 g of yellow ferric oxide was sprayed, followed by granulating and drying processes, to give granules A.

25 Separately, 872.1 g of D-mannitol (Towa Chemical

Industry Co., Ltd.: Mannit S), 112.5 g of crystalline cellulose, and 56.3 g of crospovidone were placed in a fluidized bed granulating dryer (Powrex Co., FD-3SN type), and 540 g of purified water containing 36.2 g of D-mannitol and 1.4 g of yellow ferric oxide was sprayed, followed by granulating and drying processes, to give granules B.

A 1003 g portion of granules A, 971 g of granules B, 6.3 g of light anhydrous silicic acid, 4.1 g of aspartame, and 41 g of magnesium stearate were mixed.

This mixed powder was tabletted into tablets weighing 250 mg each (Kikusui Seisakusho, Correct 12HUK, tablet size of 9.5 mm $\phi$ , compression pressure of 4.9, 9.8, and 19.6 kN /cm<sup>2</sup>).

### Example 3

A 90 g portion of manidipine hydrochloride, 416 g of D-mannitol (Merck Co.: 1.05980, mean particle diameter of 45  $\mu$ m), 189 g of corn starch, 94.5 g of crystalline cellulose, 1.7 g of light anhydrous silicic acid, and 47.3 g of crospovidone were placed in a fluidized bed granulating dryer (Powrex Co., FD-3SN type), and 423 g of purified water containing 33.5 g of D-mannitol and 0.4 g of yellow ferric oxide was sprayed, followed by granulating and drying processes, to give granules C.



Separately, 884 g of D-mannitol (Towa Chemical Industry Co., Ltd.: Mannit S), 105 g of crystalline cellulose, and 52.5 g of crospovidone were placed in a fluidized bed granulating dryer (Powrex Co., FD-3SN type), and 540 g of purified water containing 35.7 g of D-mannitol and 0.4 g of yellow ferric oxide was sprayed, followed by granulating and drying processes, to give granules D.

A 760 g portion of granules C, 845 g of granules D, 5.1 g of light anhydrous silicic acid, 3.9 g of aspartame, and 33 g of magnesium stearate were mixed.

This mixed powder was tabletted into tablets weighing 210 mg each (Kikusui Seisakusho, Correct 12HUK, tablet size of 9.0 mm $\phi$ , compression pressure of 9.8 kN/cm<sup>2</sup>).

#### Example 4

An 80 g portion of manidipine hydrochloride, 220 g of D-mannitol (Merck Co.: 1.05980, mean particle diameter of 45  $\mu$ m), 100 g of corn starch, and 1.2 g of light anhydrous silicic acid were placed in a fluidized bed granulating dryer (Powrex Co., LAB-1 type), and 200 g of purified water containing 6 g of hydroxypropylcellulose (Nippon Soda Co., Ltd.) and 0.4 g of yellow ferric oxide was sprayed, followed by granulating and drying processes,

to give granules E.

Separately, 400.5 g of D-mannitol (Towa Chemical Industry Co., Ltd.: Mannit S), and 100 g of crystalline cellulose were placed in a fluidized bed granulating dryer (Powrex Co., LAB-1 type), and 180 g of purified water containing 16.1 g of D-mannitol and 0.8 g of yellow ferric oxide was sprayed, followed by granulating and drying processes, to give granules F.

A 203.8 g portion of granules E, 258.8 g of granules F, 25 g of crospovidone, 1.4 g of light anhydrous silicic acid, 1 g of aspartame, and 10 g of magnesium stearate were mixed.

This mixed powder was tabletted into tablets weighing 250 mg each (Kikusui Seisakusho, Correct 12HUK, tablet size of 9.5 mm $\phi$ , compression pressure of 9.8 kN/cm<sup>2</sup>).

#### Example 5

A 289 g portion of D-mannitol (Towa Chemical Industry Co., Ltd.: Mannit S), 40 g of crystalline cellulose, 40 g of corn starch, and 1.2 g of light anhydrous silicic acid were placed in a fluidized bed granulating dryer (Powrex Co., LAB-1 type), and 120 g of purified water containing 0.4 g of voglibose and 10 mg of Food Yellow No.5 was sprayed, followed by granulating and

drying processes, to give granules.

To 296 g of the granules, 16 g of crospovidone, 0.32 g of light anhydrous silicic acid, 6.4 g of magnesium stearate, and 0.96 g of aspartame were added, to give a mixed powder.

This mixed powder was tabletted into tablets weighing 200 mg each (Kikusui Seisakusho, Correct 12HUK, tablet size of 9.0 mm $\phi$ , compression pressure of 9.8 kN/cm<sup>2</sup>).

#### Example 6

A 16 g portion of candesartan cilexetil, 273 g of D-mannitol (Towa Chemical Industry Co., Ltd.: Mannit S), 40 g of crystalline cellulose, 40 g of corn starch, and 1.2 g of light anhydrous silicic acid were placed in a fluidized bed granulating dryer (Powrex Co., LAB-1 type), and 120 g of purified water was sprayed, followed by granulating and drying processes, to give granules.

To 296 g of the granules, 16 g of crospovidone, 0.32 g of light anhydrous silicic acid, 6.4 g of magnesium stearate, and 0.96 g of aspartame were added, to give a mixed powder.

This mixed powder was tabletted into tablets weighing 200 mg each (Kikusui Seisakusho, Correct 12HUK, tablet size of 9.0 mm $\phi$ , compression pressure of 9.8

kN/cm<sup>2</sup>).

Example 7

A 660 mg portion of pioglitazone hydrochloride, 2670  
5 mg of D-mannitol (Towa Chemical Industry Co., Ltd.:  
Mannit S), 500 mg of crystalline cellulose, 500 mg of  
corn starch, 500 mg of crospovidone, 20 mg of light  
anhydrous silicic acid, 100 mg of magnesium stearate, and  
50 mg of aspartame were mixed in a tablet bottle.

10 This mixed powder was tabletted into tablets  
weighing 250 mg each (Shimadzu Corporation, Universal  
testing machine UH-10A, tablet size of 9.5 mm $\phi$ ,  
compression pressure of 9.8 kN/cm<sup>2</sup>).

15 Example 8

A 900 g portion of manidipine hydrochloride, 1374.8  
g of granulated lactose powder (Freund Sangyo.: Dilactose  
S, mean particle diameter of 80  $\mu$ m), 301.5 g of  
crospovidone, and 211.5 g of corn starch (Japan Corn  
20 Starch) were placed in a fluidized bed granulating dryer  
(Fuji Sangyo Co., Ltd., FD-5S type), and 4500 g of  
purified water containing 225 g of hydroxypropylcellulose  
(Nippon Soda Co., Ltd.) and 2.3 g of yellow ferric oxide  
was sprayed, followed by granulating and drying processes,  
25 to give granules G. The granules G were sized at the

screen size (1.0 mm $\phi$ ) by a power mill (Showa Kagaku Kikai Kosakusho, P-3), to give sized granules G.

Separately, 2856 g of D-mannitol (Towa Chemical Industry Co., Ltd.: Mannit S), 1650 g of D-mannitol (Merck Co.: 1.05980), and 249 g of crospovidone were placed in a fluidized bed granulating dryer (Fuji Sangyo Co., Ltd., FD-5S type), and 1500 g of purified water containing 150 g of D-mannitol (Towa Chemical Industry Co., Ltd.: Mannit S), 7.5 g of yellow ferric oxide, and 37.5 g of anhydrous citric acid was sprayed, followed by granulating and drying processes, to give granules H. The granules G were sized at the screen size (1.0 mm) by a power mill, to give sized granules H.

A 737 g portion of sized granules G, 1815 g of sized granules H, 151.3 g of crystalline cellulose, 5.5 g of aspartame, and 41.3 g of magnesium stearate were mixed. This mixed powder was tabletted into tablets weighing 250 mg each (Kikusui Seisakusho, Correct 12HUK, tablet size of 9.5 mm $\phi$ , compression pressure of 7.4 kN /cm<sup>2</sup>).

#### Example 9

A 44 g portion of manidipine hydrochloride, 442.4 g of trehalose (Asahi Chemical Industry Co., Ltd.: Trehalose P, mean particle diameter of 44  $\mu$ m), and 33 g of crospovidone were placed in a fluidized bed

granulating dryer (Powrex Co., LAB-1 type), and 231 g of purified water containing 11 g of hydroxypropylcellulose was sprayed, followed by granulating and drying processes, to give granules.

5        A 459.4 g portion of the granules, 27.2 g of crystalline cellulose, 1.0 g of aspartame, and 7.4 g of magnesium stearate were mixed.

10       This mixed powder was tabletted into tablets weighing 250 mg each (Kikusui Seisakusho, Correct 19KAWC, tablet size of 9.5 mm $\phi$ , compression pressure of 2.9 kN/cm<sup>2</sup>).

#### Example 10

15       Trehalose (Asahi Chemical Industry Co., Ltd.: Trehalose G, mean particle diameter of 346  $\mu$ m) was pulverized with a power mill (Showa Kagaku Kikai Kosakusho, P-3) at the screen size (0.5 mm $\phi$ ), to give a powder with the mean particle diameter of 185  $\mu$ m.

20       This pulverized trehalose was used in place of the trehalose in Example 9, and processed under the same conditions as those in Example 9, to give tablets.

#### Example 11

25       Erythritol (Nikkenn Chemicals Co., Ltd.: mean particle diameter of 474  $\mu$ m) was pulverized with a power

mill (Showa Kagaku Kikai Kosakusho, P-3) at the screen size (0.5 mm $\phi$ ), to give a powder with the mean particle diameter of 178  $\mu$ m.

5 This pulverized erythritol was used in place of the trehalose in Example 9, and processed under the same conditions as those in Example 9, to give tablets. (compression pressure 7.4 kN/cm<sup>2</sup>)

#### Example 12

10 Xylitol (Towa Chemical Industry Co., Ltd.: Xylit XC, mean particle diameter of 363  $\mu$ m) was pulverized with a power mill (Showa Kagaku Kikai Kosakusho, P-3) at the screen size (0.5 mm $\phi$ ), to give a powder with the mean particle diameter of 135  $\mu$ m.

15 A 50 g portion of manidipine hydrochloride, the pulverized xylitol, 37.5 g of crospovidone, 15.6 g of crystalline cellulose, and 9.4 g of magnesium stearate were mixed.

20 This mixed powder was tabletted into tablets weighing 250 mg each (Shimadzu Corporation, Universal testing machine UH-10A, tablet size of 9.5 mm $\phi$ , compression pressure of 14.7 kN /cm<sup>2</sup>).

#### Example 13

25 A 50 g portion of manidipine hydrochloride, maltitol

(LESYS of Towa Chemical Industry Co., Ltd., mean particle diameter of 181  $\mu\text{m}$ ), 37.5 g of crospovidone, 15.6 g of crystalline cellulose, and 9.4 g of magnesium stearate were mixed.

5           This mixed powder was tabletted into tablets weighing 250 mg each (Shimadzu Corporation, Universal testing machine UH-10A, tablet size of 9.5 mm $\phi$ , compression pressure of 9.8 kN /cm<sup>2</sup>).

10   Example 14

Erythritol (Nikkenn Chemicals Co., Ltd.: mean particle diameter of 474  $\mu\text{m}$ ) was pulverized with a jet mill (Nippon Pneumatic MFG Co., Ltd., PJM-100SP), to give a powder with the mean particle diameter of 75  $\mu\text{m}$ .

15           This pulverized erythritol was used in place of the trehalose in Example 9, and processed under the same conditions as those in Example 9, to give tablets.

Example 15

20           Sorbitol (Sorbitol DP-50M of Towa Chemical Industry Co., Ltd., mean particle diameter of 172  $\mu\text{m}$ ) was pulverized with a jet mill (Nippon Pneumatic MFG Co., Ltd., PJM-100SP), to give a powder with the mean particle diameter of 43  $\mu\text{m}$ .

25           A 25 g portion of manidipine hydrochloride, the



pulverized sorbitol, 18.8 g of crospovidone, 7.8 g of crystalline cellulose, and 4.7 g of magnesium stearate were mixed.

5 This mixed powder was tabletted into tablets weighing 125 mg each (Shimadzu Corporation, Universal testing machine UH-10A, tablet size of 8.5 mm $\phi$ , compression pressure of 2.9 kN /cm<sup>2</sup>).

Comparative Example 1

10 D-Mannitol with the mean particle diameter of 21  $\mu$ m (Merck Co.: 1.05988) was used in place of the D-mannitol in Example 1, and processed under the same conditions as those in Example 1, to give tablets.

15 Comparative Example 2

D-Mannitol with the mean particle diameter of 21  $\mu$ m (Merck Co.: 1.05988) was used in place of the D-mannitol in Example 5, and processed under the same conditions as those in Example 5, to give tablets.

20

Comparative Example 3

Trehalose (Asahi Chemical Industry Co., Ltd.: Trehalose G) was pulverized with the atomizer (Fuji Paudal Co., Ltd., KII-2), to give a powder with the mean  
25 particle diameter of 19  $\mu$ m.

This pulverized trehalose was used in place of the trehalose in Example 9, and processed under the same conditions as those in Example 9, to give tablets.

The results of measurement of the hardness and the intraoral disintegration time of the tablets obtained in the Examples and Comparative Examples by the above-mentioned test methods, and the results of evaluation of productivity based on the observation of fluidity, binding property, and adhesion of powder to the surface of the punch during production of tablets are summarized in Table 1.

Table 1

Productivity, hardness, and intraoral disintegration time  
of tablets

	Tabletting pressure (kN/cm <sup>2</sup> )	Fluidity during tabletting	Binding property	Adhesion to punch	Hardness (N)	Intraoral disintegration time (second)
Example 1	9.8	good	absent	absent	37	25
Example 2	4.9	good	absent	absent	17	17
	9.8	good	absent	absent	39	16
	19.6	good	absent	absent	50	20
Example 3	9.8	good	absent	absent	24	17
Example 4	9.8	good	absent	absent	25	24
Example 5	9.8	good	absent	absent	26	19
Example 6	9.8	good	absent	absent	26	13
Example 7	9.8	good	absent	absent	33	25
Example 8	7.4	good	absent	absent	29	22
Example 9	2.9	good	absent	absent	21	52
Example 10	2.9	good	absent	absent	16	43
Example 11	7.4	good	absent	absent	36	31
Example 12	14.7	good	absent	absent	16	61
Example 13	9.8	good	absent	absent	21	51
Example 14	2.9	good	absent	absent	17	38
Example 15	2.9	good	absent	absent	16	67
Comparative Example 1	9.8	insufficient	present	present	49	26
Comparative Example 2	9.8	insufficient	present	present	33	21
Comparative Example 3	2.9	insufficient	present	present	25	36

## 5 INDUSTRIAL APPLICABILITY

Quickly disintegrating solid preparations, preferably intraorally quickly disintegrating solid preparations, more preferably intraorally quickly disintegrating tablets of the invention obtained by the



## CLAIMS

1. A quickly disintegrating solid preparation comprising a) an active ingredient, b) a saccharide or sugar alcohol with the mean particle diameter of 30  $\mu\text{m}$  to 300  $\mu\text{m}$ , c) a disintegrating agent, and d) a cellulose compound.

2. The preparation according to claim 1, which is an intraorally quickly disintegrating solid preparation.

3. The preparation according to claim 1, which is a tablet preparation.

4. The preparation according to claim 1, which contains 40 to 95 parts of a saccharide or sugar alcohol per 100 parts of the solid preparation by weight.

5. The preparation according to claim 1, which contains 0.5 to 15 parts of a disintegrating agent per 100 parts of the solid preparation by weight.

6. The preparation according to claim 1, which contains 0.5 to 40 parts of a cellulose compound per 100 parts of the solid preparation by weight.

7. The preparation according to claim 1, wherein the saccharide is one or more saccharides selected from the group consisting of glucose, fructose, lactose, sucrose, and trehalose.

8. The preparation according to claim 1, wherein the saccharide is lactose.

9. The preparation according to claim 1, wherein the sugar alcohol is one or more sugar alcohols selected from the group consisting of D-mannitol, erythritol, xylitol, maltitol, and sorbitol.

5 10. The preparation according to claim 1, wherein the sugar alcohol is D-mannitol.

11. The preparation according to claim 1, characterized in that D-mannitol with the mean particle diameter of 30  $\mu\text{m}$  to 300  $\mu\text{m}$  is used as the saccharide or  
10 sugar alcohol with the mean particle diameter of 30  $\mu\text{m}$  to 300  $\mu\text{m}$ .

12. The preparation according to claim 1, wherein the disintegrating agent is one or more disintegrating agents selected from the group consisting of carmellose  
15 calcium, carboxymethylstarch sodium, croscarmellose sodium, and crospovidone.

13. The preparation according to claim 1, wherein the cellulose compound is one or more cellulose compounds selected from the group consisting of crystalline  
20 cellulose, powder cellulose, low substituted hydroxypropylcellulose, and carmellose.

14. The preparation according to claim 1, wherein the active ingredient is manidipine hydrochloride.

15 25 15. The preparation according to claim 1, wherein the active ingredient is voglibose.

16. The preparation according to claim 1, wherein the active ingredient is candesartan cilexetil.

17. The preparation according to claim 1, wherein the active ingredient is pioglitazone hydrochloride.

5 18. The procedure for production of the preparation according to claim 1, characterized in that a mixture containing a) an active ingredient, b) a saccharide or sugar alcohol with the mean particle diameter of 30  $\mu\text{m}$  to 300  $\mu\text{m}$ , c) a disintegrating agent, and d) a cellulose  
10 compound is subjected to compression molding.

19. A quickly disintegrating solid preparation comprising a) an active ingredient, b-1) a saccharide or sugar alcohol with the mean particle diameter of 5  $\mu\text{m}$  to below 90  $\mu\text{m}$ , b-2) a saccharide or sugar alcohol with the  
15 mean particle diameter of 90  $\mu\text{m}$  to 500  $\mu\text{m}$ , c) a disintegrating agent, and d) a cellulose compound.

20. The preparation according to claim 19, which contains 0.1 to 10 parts of the ingredient b-2) per 1 part of the ingredient b-1) by weight.

20 21. The preparation according to claim 19, characterized in that a mixture of the ingredient b-1) and the ingredient b-2) is used as the ingredient b-1) and the ingredient b-2).

22. The preparation according to claim 21, wherein  
25 the mean particle diameter of the mixture is 30  $\mu\text{m}$  to 300

μm.

23. The preparation according to claim 19, wherein the mean particle diameter of the ingredient b-1) is 30 μm to below 90 μm.

5 24. The preparation according to claim 19, wherein the mean particle diameter of the ingredient b-1) is 35 μm to 80 μm.

25. The preparation according to claim 19, wherein the mean particle diameter of the ingredient b-2) is 90 μm to 300 μm.

26. The preparation according to claim 19, wherein the mean particle diameter of the ingredient b-2) is 90 μm to 200 μm.

27. The preparation according to claim 19, wherein the saccharide is one or more saccharides selected from the group consisting of glucose, fructose, lactose, sucrose, and trehalose.

28. The preparation according to claim 19, wherein the sugar is lactose.

29. The preparation according to claim 19, wherein the sugar alcohol is one or more sugar alcohols selected from the group consisting of D-mannitol, erythritol, xylitol, maltitol, and sorbitol.

30. The preparation according to claim 19, wherein the sugar alcohol is D-mannitol.



31. The preparation according to claim 19, characterized in that D-mannitol with the mean particle diameter of 30  $\mu\text{m}$  to below 90  $\mu\text{m}$  and D-mannitol with the mean particle diameter of 90  $\mu\text{m}$  to 300  $\mu\text{m}$  are used as the  
5 ingredient b-1) and the ingredient b-2), respectively.

32. The procedure for production of the preparation according to claim 19, characterized in that a mixture containing a) an active ingredient, b-1) a saccharide or sugar alcohol with the mean particle diameter of 5  $\mu\text{m}$  to  
10 below 90  $\mu\text{m}$ , b-2) a saccharide or sugar alcohol with the mean particle diameter of 90  $\mu\text{m}$  to 500  $\mu\text{m}$ , c) a disintegrating agent, and d) a cellulose compound is subjected to compression molding.

**DECLARATION AND POWER OF ATTORNEY FOR U.S. PATENT APPLICATION**

( ) Original ( ) Supplemental ( ) Substitute (X) PCT ( ) Design

As a below named inventor, I hereby declare that: my residence, post office address and citizenship are as stated below next to my name; that I verily believe that I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural inventors are named below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

Title: **QUICKLY DISINTEGRATING SOLID PREPARATIONS**

of which is described and claimed in:

- ( ) the attached specification, or  
 ( ) the specification in the application Serial No. \_\_\_\_\_ filed \_\_\_\_\_;  
 and with amendments through \_\_\_\_\_ (if applicable), or  
 (X) the specification in International Application No. PCT/JP00/03923, filed June 16, 2000, and as amended on \_\_\_\_\_ (if applicable).

I hereby state that I have reviewed and understand the content of the above-identified specification, including the claims, as amended by any amendment(s) referred to above.

I acknowledge my duty to disclose to the Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, '1.56.

I hereby claim priority benefits under Title 35, United States Code, '119 (and '172 if this application is for a Design) of any application(s) for patent or inventor's certificate listed below and have also identified below any application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

COUNTRY	APPLICATION NO.	DATE OF FILING	PRIORITY CLAIMED
Japan	172532/1999	June 18, 1999	Yes


I hereby claim the benefit under Title 35, United States Code '120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code '112, I acknowledge the duty to disclose information material to patentability as defined in Title 37, Code of Federal Regulations, '1.56 which occurred between the filing date of the prior application and the national or PCT international filing date of this application.

APPLICATION SERIAL NO.	U.S. FILING DATE	STATUS: PATENTED, PENDING, ABANDONED

And I hereby appoint Michael R. Davis, Reg. No. 25,134; Matthew M. Jacob, Reg. No. 25,154; Warren M. Cheek, Jr., Reg. No. 33,367; Nils Pedersen, Reg. No. 33,145; Charles R. Watts, Reg. No. 33,142; and Michael S. Huppert, Reg. No. 40,268, who together constitute the firm of WENDEROTH, LIND & PONACK, L.L.P., as well as any other attorneys and agents associated with Customer No. 000513, to prosecute this application and to transact all business in the U.S. Patent and Trademark Office connected therewith.

I hereby authorize the U.S. attorneys and agents named herein to accept and follow instructions from AOYAMA & PARTNERS, as to any action

to be taken in the U.S. Patent and Trademark Office regarding this application without direct communication between the U.S. attorneys and myself. In the event of a change in the persons from whom instructions may be taken, the U.S. attorneys named herein will be so notified by me.

Direct Correspondence to Customer No:   <b>000513</b> PATENT TRADEMARK OFFICE	Direct Telephone Calls to:  WIENDEROTH, LIND & PONACK, L.L.P. 2033 "K" Street, N.W., Suite 800 Washington, D.C. 20006-1021  Phone (202) 721-8200 Fax (202) 721-8250
--	--

Full Name of First Inventor	FAMILY NAME <u>OHKOUCHI</u>	FIRST GIVEN NAME <u>Kazuhiro</u>	SECOND GIVEN NAME
Residence & Citizenship	CITY <u>Toyonaka-shi</u>	STATE OR COUNTRY <u>Japan</u>	COUNTRY OF CITIZENSHIP <u>Japan</u>
Post Office Address	ADDRESS <u>7-15, Eirakuso 1-chome, Toyonaka-shi, Osaka, Japan</u>	CITY	STATE OR COUNTRY ZIP CODE

Full Name of Second Inventor	FAMILY NAME <u>KOYAMA</u>	FIRST GIVEN NAME <u>Hiroyoshi</u>	SECOND GIVEN NAME
Residence & Citizenship	CITY <u>Mishima-gun</u>	STATE OR COUNTRY <u>Japan</u>	COUNTRY OF CITIZENSHIP <u>Japan</u>
Post Office Address	ADDRESS <u>2-20-204, Wakayamadai 2-chome, Shimamoto-cho, Mishima-gun, Osaka, Japan</u>	CITY	STATE OR COUNTRY ZIP CODE

Full Name of Third Inventor	FAMILY NAME	FIRST GIVEN NAME	SECOND GIVEN NAME
Residence & Citizenship	CITY	STATE OR COUNTRY	COUNTRY OF CITIZENSHIP
Post Office Address	ADDRESS	CITY	STATE OR COUNTRY ZIP CODE

Full Name of Fourth Inventor	FAMILY NAME	FIRST GIVEN NAME	SECOND GIVEN NAME
Residence & Citizenship	CITY	STATE OR COUNTRY	COUNTRY OF CITIZENSHIP
Post Office Address	ADDRESS	CITY	STATE OR COUNTRY ZIP CODE

1st Inventor Hagahiro Okouchi Date 2001/09/14  
2nd Inventor Idiragoshi Koyama Date 2001/09/14  
3rd Inventor \_\_\_\_\_ Date \_\_\_\_\_  
4th Inventor \_\_\_\_\_ Date \_\_\_\_\_

1st Inventor Hagahiro Okouchi Date 2001/09/14  
2nd Inventor Idiragoshi Koyama Date 2001/09/14  
3rd Inventor \_\_\_\_\_ Date \_\_\_\_\_  
4th Inventor \_\_\_\_\_ Date \_\_\_\_\_

U.S. Application Serial No. \_\_\_\_\_ Filing Date \_\_\_\_\_  
Applicant Reference Number \_\_\_\_\_ Atty Docket No. \_\_\_\_\_

Title of Invention \_\_\_\_\_

*(continued)*

Page 3 of 3